Impact of prior thalidomide (T) therapy on the efficacy of pegylated liposomal doxorubicin (PLD) and bortezomib (B) in relapsed/refractory multiple myeloma (RRMM)

被引：0
|
作者：
Sonneveld, P.
Hajek, R.
Nagler, A.
Spencer, A.
Blade, J.
Robak, T.
Zhuang, S. H.
Harousseau, J. L.
Fruchtman, S.
Orlowski, R. Z.
机构：
[1] Erasmus MC, Rotterdam, Netherlands
[2] Interni Hematoonkol Klin Fak Brno, Brno, Czech Republic
[3] Chaim Sheba Med Ctr, Tel Hashomer, Israel
[4] Alfred Hosp, Melbourne, Vic, Australia
[5] Hosp Clin Barcelona, Barcelona, Spain
[6] Med Univ Lodz, Lodz, Poland
[7] J&J Pharmaceut Res & Dev LLC, Raritan, NJ USA
[8] Univ Hosp Hotel Dieu, Nantes, France
[9] Ortho Biotech Clin Affairs LLC, Bridgewater, NJ USA
[10] Univ N Carolina, Chapel Hill, NC 27515 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8023
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Pegylated liposomal doxorubicin and bortezomib in relapsed/refractory multiple myeloma
    不详
    [J]. CLINICAL LYMPHOMA & MYELOMA, 2007, 7 (07): : 453 - 455
  • [2] Safety and efficacy of pomalidomide (POM), dexamethasone (DEX), and pegylated liposomal doxorubicin (PLD) for patients with relapsed/refractory multiple myeloma (RRMM).
    Berenson, James R.
    Stampleman, Laura
    Bessudo, Alberto
    Rosen, Peter
    Klein, Leonard M.
    Woliver, Thomas B. S.
    Flam, Marshall S.
    Eshaghian, Shahrooz
    Nassir, Youram
    Swift, Regina A.
    Vescio, Robert A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] A retrospective review of pegylated liposomal doxorubicin (PLD), bortezomib, and dexamethasone (DVD) for relapsed or refractory (R/R) multiple myeloma (MM)
    Waterman, G. N.
    Yellin, O.
    Swift, R. A.
    Hilger, J.
    Berenson, J. R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [4] Liposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myeloma
    Ning, Yang-Min
    He, Kun
    Dagher, Ramz
    Sridhara, Rajeshwari
    Farrell, Ann T.
    Justice, Robert
    Pazdur, Richard
    [J]. ONCOLOGY-NEW YORK, 2007, 21 (12): : 1503 - 1508
  • [5] Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy
    Sonneveld, Pieter
    Hajek, Roman
    Nagler, Arnon
    Spencer, Andrew
    Blade, Joan
    Robak, Tadeusz
    Zhuang, Sen H.
    Harousseau, Jean-Luc
    Orlowski, Robert Z.
    [J]. CANCER, 2008, 112 (07) : 1529 - 1537
  • [6] Salvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory myeloma patients
    Romano, Alessandra
    Chiarenza, Annalisa
    Conticello, Concetta
    Cavalli, Maide
    Vetro, Calogero
    Di Raimondo, Cosimo
    Cunsolo, Rosario
    Palumbo, Giuseppe Alberto
    Di Raimondo, Francesco
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2014, 93 (03) : 207 - 213
  • [7] Pegylated Liposomal Doxorubicin plus Bortezomib in Relapsed or Refractory Multiple Myeloma: Efficacy and Safety in Patients with Renal Function Impairment
    Blade, Joan
    Sonneveld, Pieter
    Miguel, Jesus E. San
    Sutherland, Heather J.
    Hajek, Roman
    Nagler, Arnon
    Spencer, Andrew
    Robak, Tadeusz
    Cibeira, M. Teresa
    Zhuang, Sen H.
    Harousseau, Jean-Luc
    Orlowski, Robert Z.
    [J]. CLINICAL LYMPHOMA & MYELOMA, 2008, 8 (06): : 352 - 355
  • [8] A phase 1/2 study of pomalidomide (POM), dexamethasone (DEX), and pegylated liposomal doxorubicin (PLD) for patients with relapsed/refractory multiple myeloma (RRMM)
    Berenson, James R.
    Klein, Leonard M.
    Rosen, Peter J.
    Woliver, Thomas B. S.
    Eshaghlan, Shahrooz
    Nassir, Youram
    Swift, Regina A.
    Vescio, Robert A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [9] Weekly Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone Is a Safe and Effective Therapy for Elderly Patients With Relapsed/Refractory Multiple Myeloma
    Gozzetti, Alessandro
    Fabbri, Alberto
    Oliva, Stefania
    Marchini, Elena
    Bocchia, Monica
    Defina, Marzia
    Lauria, Francesco
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2010, 10 (01): : 68 - 72
  • [10] Bortezomib, liposomal doxorubicin and dexamethasone combination therapy for patients with relapsed or refractory multiple myeloma
    Falcone, A.
    Sanpaolo, G.
    Bodenizza, C.
    Carella, A. M.
    Dell'Olio, M.
    Mantuano, S.
    Melillo, L.
    Merla, E.
    Scalzulli, F.
    Cascavilla, N.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 147 - 148
12345